Search results
GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Key Points
- Interested in GitLab Inc.? Here are five stocks we like better.
- GitLab reported Q1 revenue of nearly $265 million, up 23% year over year, with adjusted EPS of 23 cents, beating
GitLab’s Price Recovery Gains Traction—Time to Get On Board?
GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Align Technology CFO: Global Growth, DSOs Offset North America Demand Pressure
Key Points
- Interested in Align Technology, Inc.? Here are five stocks we like better.
- Align Technology said international markets and North American DSOs are offsetting weakness in the U.S
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End
Key Points
- Interested in Alvotech? Here are five stocks we like better.
- Alvotech says it is at an “inflection point,” with management expecting five U.S. biosimilars on the market by year-end
Does InfuSystems Holdings (INFU) Have the Potential to Rally 62.61% as Wall Street Analysts Expect?
InfuSystems Holdings, Inc. (INFU) closed the last trading session at $9.12, gaining 1.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets
Wall Street Analysts Predict a 40.57% Upside in Omnicell (OMCL): Here's What You Should Know
Shares of Omnicell (OMCL) have gained 0.6% over the past four weeks to close the last trading session at $43.6, but there could still be a solid upside left in the stock if short-term price targets
Wall Street Analysts See a 27.97% Upside in Tecogen (TGEN): Can the Stock Really Move This High?
Tecogen Inc. (TGEN) closed the last trading session at $6.9, gaining 43.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know
Cencora (COR) closed the last trading session at $270.32, gaining 5.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
D-Wave Unveils Fault-Tolerant Quantum Computing Plan: What's Ahead?
D-Wave Quantum QBTS or D-Wave is advancing its push toward commercial, fault-tolerant quantum computing. The company recently laid out a new gate-model roadmap, targeting 100 logical qubits capable
Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference
Key Points
- Interested in Chime Financial, Inc.? Here are five stocks we like better.
- Chime CEO Chris Britt said the company is focused on building primary checking relationships with mainstream
Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference
Chime Financial CEO Maps Growth Roadmap, $2.7B Revenue Target at Conference
BASF Bets on China Growth as Zhanjiang Site Targets €5 Billion in Sales by 2030
Key Points
- Interested in Basf Se? Here are five stocks we like better.
- BASF’s new Zhanjiang Verbund site in Guangdong has started operations on schedule and below budget, marking the company’s
Wall Street Analysts See a 30.09% Upside in Accelerant Holdings (ARX): Can the Stock Really Move This High?
Accelerant Holdings (ARX) closed the last trading session at $14.99, gaining 13.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Predict a 41.87% Upside in Veeva (VEEV): Here's What You Should Know
Veeva Systems (VEEV) closed the last trading session at $172.61, gaining 3.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Does TSS (TSSI) Have the Potential to Rally 29.52% as Wall Street Analysts Expect?
TSS Inc. (TSSI) closed the last trading session at $13.38, gaining 11.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Think ABCELLERA BIOLG (ABCL) Could Surge 85.59%: Read This Before Placing a Bet
AbCellera Biologics Inc. (ABCL) closed the last trading session at $5.62, gaining 7.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Wall Street Analysts Predict a 46.47% Upside in Sprinklr (CXM): Here's What You Should Know
Shares of Sprinklr (CXM) have gained 0.9% over the past four weeks to close the last trading session at $5.38, but there could still be a solid upside left in the stock if short-term price targets
ALT and the Rise of Dual Agonists Targeting Liver Disease
Altimmune ALT is trying to ride a clear shift in liver drug development. Programs are increasingly designed to hit multiple pathways at once, rather than relying on a single lever like weight loss
How FIS and Fuse Are Targeting the Quiet Cost of Outdated Lending Tech
Fidelity National Information Services, Inc. FIS recently formed a strategic partnership with Fuse, a cloud-native loan origination platform, to build a modern end-to-end origination solution for
Wall Street Analysts See a 34.66% Upside in NetEase (NTES): Can the Stock Really Move This High?
Shares of NetEase (NTES) have gained 2.1% over the past four weeks to close the last trading session at $118.7, but there could still be a solid upside left in the stock if short-term price targets